-
Mashup Score: 11
Dowdy Jackson, Ph.D.Jackson Consulting GroupMay 10th 2024 AbstractAntibody drug conjugates (ADCs) have become one of the most sought after modalities to treat cancer patients. Several high-profile deals have been announced recently between smaller biotech companies developing ADCs and larger companies looking to enhance their oncology pipelines. There is significant competition in the ADC space and one of the key questions for companies developing ADCs is how can they differentiate from their co
Source: www.jackson-consulting-group.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 11
Dowdy Jackson, Ph.D.Jackson Consulting GroupMay 10th 2024 AbstractAntibody drug conjugates (ADCs) have become one of the most sought after modalities to treat cancer patients. Several high-profile deals have been announced recently between smaller biotech companies developing ADCs and larger companies looking to enhance their oncology pipelines. There is significant competition in the ADC space and one of the key questions for companies developing ADCs is how can they differentiate from their co
Source: www.jackson-consulting-group.comCategories: General Medicine News, Oncologists2Tweet-
RT @EGFRResisters: Bispecific ADCs: A potential game changer for the next generation of ADCs https://t.co/MQuroJxXDP https://t.co/H5OLQ90t…
-
-
Mashup Score: 11
Dowdy Jackson, Ph.D.Jackson Consulting GroupMay 10th 2024 AbstractAntibody drug conjugates (ADCs) have become one of the most sought after modalities to treat cancer patients. Several high-profile deals have been announced recently between smaller biotech companies developing ADCs and larger companies looking to enhance their oncology pipelines. There is significant competition in the ADC space and one of the key questions for companies developing ADCs is how can they differentiate from their co
Source: www.jackson-consulting-group.comCategories: General Medicine News, Oncologists2Tweet-
RT @EGFRResisters: Bispecific ADCs: A potential game changer for the next generation of ADCs https://t.co/MQuroJxXDP https://t.co/H5OLQ90t…
-
-
Mashup Score: 3Erman Akkus: NSCLC and anti-EGFR treatments from the ASCO Educational Book - OncoDaily - 8 month(s) ago
Erman Akkus: NSCLC and anti-EGFR treatments from the ASCO Educational Book / ADAURA, ADAURA2, ADJUVANT/CTONG 1104, Ankara University, anti-EGFR treatments,
Source: oncodaily.comCategories: General Medicine News, Oncologists2Tweet-
RT @oncodaily: NSCLC and anti-EGFR treatments from the ASCO Educational Book - @Erman_Akkus @ASCO https://t.co/zEKMDSVysy #ADAURA #ADAURA…
-
-
Mashup Score: 1instagram - 8 month(s) ago
A virtual Experts Knowledge Share on the topic of ‘Precision oncology in practice – The journey from testing to treatment in lung and prostate cancer’ chaired by Prof. Fernando López-Ríos (Spain) and co-chaired by Assoc. Prof. Alicia Morgans (US) and Assoc. Prof. Herbert Loong (Hong Kong) This event is in collaboration with PRECISION ONCOLOGY CONNECT, a group of international experts in the field of detection and treatment of targetable genetic/genomic alterations in various cancers. You will also have
Source: engage.cor2ed.comCategories: General Medicine News, Oncologists2Tweet-
RT @PresOnc_Connect: The countdown is on! Join the virtual event on the 30th April REGISTER NOW 👉https://t.co/mnP3LWW9Tc Learn all about…
-
-
Mashup Score: 1
Learn the latest about epithelioid hemangioendothelioma (EHE) research and clinical management from an international group of experts and attendees on Friday, April 19, 2024.
Source: fightehe.orgCategories: General Medicine News, Oncologists2Tweet-
RT @EHEfoundation: Join us for the 2024 EHE 360 Global Patient Conference on 4/19/24, 11am-3pm ET. Register: https://t.co/efmLAebRbG FEA…
-
-
Mashup Score: 2Current and Future Treatments of Vascular Cognitive Impairment - 8 month(s) ago
Correspondence to: Vincent Chung Tong Mok, MD, Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, 30-32, Ngan Shing St, New Territories, Hong Kong SAR, China. Email For Sources of Funding and Disclosures, see page 832. Correspondence to: Vincent Chung Tong Mok, MD, Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, 30-32, Ngan Shing St, New Territories, Hong
Source: www.ahajournals.orgCategories: General Medicine News, Oncologists2Tweet-
RT @IpBonaventure: Current and Future Treatments of Vascular Cognitive Impairment | Stroke https://t.co/cioDXcHY9v A review on treatments o…
-
-
Mashup Score: 1
Radiotherapy is one of the mainstay treatment modalities for the management of non-metastatic head and neck cancer (HNC). Notable improvements in trea…
Source: www.sciencedirect.comCategories: General Medicine News, Oncologists2Tweet-
RT @IpBonaventure: Neurological complications of modern radiotherapy for head and neck ca... https://t.co/dIJBZZU3OM
-
-
Mashup Score: 2GIST Updates from CTOS 2023 - 9 month(s) ago
Dr. Herbert Loong of the Chinese University of Hong Kong to presented “GIST Updates from CTOS 2023” to GIST patients and caregivers on November 27th at 5pm E…
Source: www.youtube.comCategories: General Medicine News, Oncologists2Tweet-
GIST Updates from CTOS 2023 https://t.co/v2yEQcqXBA via @YouTube
-
-
Mashup Score: 2EMA and EORTC soft tissue and bone sarcoma workshop - 9 month(s) agoSource: www.youtube.comCategories: General Medicine News, Oncologists2Tweet
-
EMA and EORTC soft tissue and bone sarcoma workshop https://t.co/6HoAH6GzdH via @YouTube
-
RT @EGFRResisters: Bispecific ADCs: A potential game changer for the next generation of ADCs https://t.co/MQuroJxXDP https://t.co/H5OLQ90t…